NASDAQ:VYNT

Vyant Bio Stock Forecast, Price & News

$3.31

+0.43 (+14.93 %)

(As of 05/14/2021 01:27 PM ET)

Add

Compare

Today's Range

$2.87

▼

$3.40

50-Day Range

$2.96

▼

$4.65

52-Week Range

$2.11

▼

$17.50

Volume12,820 shs

Average Volume1.96 million shs

Market Capitalization$36.43 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

30 days | 90 days | 365 days | Advanced Chart

Receive VYNT News and Ratings via Email

Sign-up to receive the latest news and ratings for Vyant Bio and its competitors with MarketBeat's FREE daily newsletter.

About Vyant Bio

Vyant Bio, Inc. operates as a biotechnology drug discovery company. The company, through its subsidiary, StemoniX, develops and manufactures at-scale human induced pluripotent stem (iPS) cell-derived neural and cardiac screening platforms for drug discovery and development. StemoniX, through collaborations with drug discovery organizations, tests compounds in-house, creates cell-based disease models, and operationalizes custom human iPSC-derived disease models for high-throughput screening. The company, through its subsidiary, vivoPharm, offers proprietary preclinical test systems supporting clinical diagnostic offerings at early stages by the pharmaceutical industry, biotechnology companies, and academic research centers. vivoPharm specializes in conducting studies to guide drug development, starting from compound libraries and ending with a set of in vitro and in vivo data and reports, as needed for investigational new drug filings. The company is based in Cherry Hill, New Jersey.

Vyant Bio (VYNT) to Release Quarterly Earnings on Tuesday
May 14, 2021 | americanbankingnews.com

Vyant Bio Announces Investor Conference Call and Webcast for First Quarter 2021
May 13, 2021 | finance.yahoo.com

Vyant Bio to Present at BioNJ’s 11th Annual BioPartnering Conference
May 11, 2021 | finance.yahoo.com

Vyant Bio (NASDAQ:VYNT) Stock Price Down 4.8%
May 1, 2021 | americanbankingnews.com

Vyant Bio Inc.
April 30, 2021 | marketwatch.com

Vyant Bio Inc
April 28, 2021 | reuters.com

VYNT.OQ - Vyant Bio Inc Profile | Reuters
April 28, 2021 | reuters.com

Cancer Genetics (NASDAQ:CGIX) Shares Pass Below 200-Day Moving Average of $3.97
April 24, 2021 | americanbankingnews.com

Cancer Genetics and StemoniX Announce Merger Closing
March 31, 2021 | finance.yahoo.com

Why Is It Moving? Analyzing The Upward Movement in Cancer Genetics's Stock Today
March 25, 2021 | benzinga.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Biotechnology

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:VYNT

Previous Symbol

CUSIPN/A

CIKN/A

Webstemonix.com

Phone201 479 1357

Employees29

Year FoundedN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book ValueN/A

Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Debt

Debt-to-Equity RatioN/A

Current RatioN/A

Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Miscellaneous

Outstanding Shares11,007,000

Market Cap$36.43 million

Next Earnings Date5/18/2021 (Confirmed)

OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

0.00 out of 5 stars

Medical Sector

2000th out of 2,039 stocks

Biotechnology Industry

144th out of 157 stocks

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Vyant Bio.

0.0 Community Rank

Outperform Votes
Vyant Bio has received 0 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Vyant Bio has received 0 “underperform” votes. (Add your “underperform” vote.)

MarketBeat's community ratings are surveys of what our community members think about Vyant Bio and other stocks. Vote “Outperform” if you believe VYNT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe VYNT will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Vyant Bio does not currently pay a dividend.
Dividend Growth
Vyant Bio does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Vyant Bio insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

See Top Rated MarketRank™ Stocks Here

Vyant Bio (NASDAQ:VYNT) Frequently Asked Questions

What stocks does MarketBeat like better than Vyant Bio?

Wall Street analysts have given Vyant Bio a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Vyant Bio wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Vyant Bio's next earnings date?

Vyant Bio is scheduled to release its next quarterly earnings announcement on Tuesday, May 18th 2021.
View our earnings forecast for Vyant Bio.

How were Vyant Bio's earnings last quarter?

Vyant Bio, Inc. (NASDAQ:VYNT) posted its earnings results on Tuesday, April, 16th. The company reported ($0.14) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.16) by $0.02. The business had revenue of $6.80 million for the quarter.
View Vyant Bio's earnings history.

How has Vyant Bio's stock been impacted by COVID-19?

Vyant Bio's stock was trading at $3.59 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, VYNT shares have decreased by 8.9% and is now trading at $3.27.
View which stocks have been most impacted by COVID-19.

Who are Vyant Bio's key executives?

Vyant Bio's management team includes the following people:

Mr. Andrew D.C. LaFrence CPA, CPA, CFO & COO (Age 58, Pay $106.07k)
Mr. Yung-Ping Yeh M.B.A., M.S., P.M.P., Chief Innovation Officer & Director
Dr. Robert J. Petcavich, Chief Science Advisor & Director (Age 67, Pay $212.48k)
Mr. John A. Roberts M.B.A., MBA, Pres, CEO & Director (Age 62)
Dr. Ralf Brandt, Pres of Discovery & Early Devel. Services (Age 53)
Dr. Barb Jones Ph.D., Sr. VP of External & Regulatory Affairs

Who are some of Vyant Bio's key competitors?

Some companies that are related to Vyant Bio include Agronomics (ANIC), ImmunoPrecise Antibodies (IPA), e-therapeutics (ETX), Verona Pharma plc (VRP.L) (VRP), Gain Therapeutics (GANX), Evaxion Biotech A/S (EVAX), Medigene (MDG1), Longeveron (LGVN), SkinBioTherapeutics (SBTX), C4X Discovery (C4XD), Acasti Pharma (ACST), Destiny Pharma (DEST), Novoheart (NVH), ReNeuron Group (RENE) and Viridian Therapeutics (VRDN).
View all of VYNT's competitors.

What is Vyant Bio's stock symbol?

Vyant Bio trades on the NASDAQ under the ticker symbol "VYNT."

Who are Vyant Bio's major shareholders?

Vyant Bio's stock is owned by many different retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (1.64%), BlackRock Inc. (1.50%), Geode Capital Management LLC (0.53%), GWM Advisors LLC (0.51%), Northern Trust Corp (0.18%) and Citigroup Inc. (0.09%).
View institutional ownership trends for Vyant Bio.

Which major investors are buying Vyant Bio stock?

VYNT stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, BlackRock Inc., Geode Capital Management LLC, GWM Advisors LLC, Northern Trust Corp, and Citigroup Inc..
View insider buying and selling activity for Vyant Bio or or view top insider-buying stocks.

How do I buy shares of Vyant Bio?

Shares of VYNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vyant Bio's stock price today?

One share of VYNT stock can currently be purchased for approximately $3.27.

How much money does Vyant Bio make?

Vyant Bio has a market capitalization of $35.99 million.

How many employees does Vyant Bio have?

Vyant Bio employs 29 workers across the globe.

What is Vyant Bio's official website?

The official website for Vyant Bio is stemonix.com.

How can I contact Vyant Bio?

The company can be reached via phone at 201 479 1357.

This page was last updated on 5/14/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Vyant Bio Stock Forecast, Price & News

Adding

Adding

Adding Vyant Bio, Inc.